USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)

  • STATUS
    Recruiting
  • End date
    Sep 2, 2023
  • participants needed
    146
  • sponsor
    Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Updated on 1 February 2021

Summary

Phase IV

Trial design : Multicentre, randomized, double-blind, placebo-controlled study

Population : Moderate to severe Crohn's disease with at least one active perianal fistula track

Investigational treatment : Group 1: Ustekinumab (UST) IntraVenous (IV) induction (6mg/kg) followed by UST SubCutaneous (SC) 90mg every 8 weeks. Group 2: Placebo IV followed by Placebo SC The trial duration for each patient will be 48 weeks.

Trial objective : To evaluate the efficacy and safety of ustekinumab in fistulizing perianal Crohn's disease.

Number of patients : A total of 146 patients will be included in 20 sites in France

Trial duration : First patient in: Q3 2020 - Last patient first visit: Q3 2022 Last patient last visit: Q3 2023

Description

Main endpoint:

The primary endpoint will be combined remission at week 12 defined as:

  • 100% of the fistula tracts without any drainage by the external openings (occurring spontaneously or after gentle finger compression) And
  • absence of collections >2 cm of the treated perianal fistulas confirmed by masked central MRI Patient requiring UST optimization will be considered in failure but will be followed until week 48

Secondary endpoints:

Definition

  • Clinical remission: 100% of the fistula tracts without any drainage by the external openings (i.e, absence of any drainage by all fistula openings occurring spontaneously or after gentle finger compression)
  • Clinical response (closure of at least 50% of all treated external openings that were draining at baseline)
  • Radiological remission: absence of collections >2 cm of the treated perianal fistulas confirmed by masked central MRI
  • Combined clinical and radiological remission at week 24 and 48.
  • Clinical remission (i.e, absence of any drainage by all fistula openings occurring spontaneously or after gentle finger compression) at week 12, 24 and 48
  • Absence of collections >2 cm of the treated perianal fistulas confirmed by masked central MRI at week 12, 24 and 48
  • Evaluation of the magnetic resonance novel index for fistula imaging in CD at week 12, 24 and 48
  • Clinical response (closure of at least 50% of all treated external openings that were draining at baseline) at week 12, 24 and 48
  • Combined clinical response and radiological remission at week 48
  • Perineal Disease Activity Index (PDAI), Crohn Disease Activity Index (CDAI) at week 12, 24 and 48
  • Quality of life will be assessed with the Inflammatory Bowel Disease questionnaire (IBDQ) scores at week 24 and 48
  • Correlation between response and remission and UST trough levels and antidrug (UST) antibodies at week 12, 24, 48
  • Clinical response of UST optimization at week 48 (closure of at least 50% of all treated external openings that were draining at week 12)
  • Clinical response at week 48 of UST introduction at W12 (closure of at least 50% of all treated external

Details
Condition Inflammatory bowel disease, Crohn's Disease, Crohn's Disease (Pediatric), crohns disease
Treatment Placebo, ustekinumab
Clinical Study IdentifierNCT04496063
SponsorGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Last Modified on1 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years
Adults with moderate to severe Crohn's disease for at least six months
Patients with at least one active perianal fistula track (between the anus or low rectum and the perineum or vulva) confirmed by MRI within the previous 12 weeks
Patients either nave to anti-TNF therapy (50%) or refractory to anti-TNF therapy (50%)
If female, subject is either not of child bearing potential, defined as post-menopausal for at least1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control during the study and for 150 days after the last dose
Condoms, sponge and foam, jellies with diaphragm or intrauterine device (IUD). IUDs may fail during azathioprine treatment. Alternative or additional contraceptive measures are advised, if azathioprine is initiated
Oral or parenteral contraceptives for 3 months prior to study drug administration
A vasectomized partner
Male subjects must agree to use an acceptable form of birth control, listed above at the start of azathioprine administration and for 90 days after last dose of azathioprine. Males should also commit to inform his partner(s) about it and to report any pregnancy to the investigator
If female, subject is not breast-feeding throughout the study and for 150 days after last dose
Subjects or his/her legal representative have voluntarily signed and dated an informed consent approved by and compliant with the requirements of this study protocol which has been approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)
Adequate cardiac, renal and hepatic function as determined by the Principal Investigator and demonstrated by Screening laboratory evaluations, questionnaires and physical examination results that do not indicate an abnormal clinical condition which would place the subject at undue risk and thus preclude subject participation in the study
Subject with a negative tuberculosis (TB) Screening Assessment [(including a Purified Protein Derivative (PPD) test < 5 mm and/or negative QuantiFERON-TB Gold test or equivalent and negative Chest X-Ray (CXR) (PA and lateral view)] at screening

Exclusion Criteria

Absence of written consent. People unable to give their consent (because of their physical or mental state)
Pregnancy or breastfeeding
Rectovaginal fistulas
Rectal and/or anal stenosis
Diverting stomas
Abscess or collections >2 cm which are not properly drained ((i.e not drained at least 3 weeks before baseline and adequately treated provided that there is no anticipated need for any further surgery)
History of colectomy
History of colonic mucosal dysplasia or adenomatous colonic polyps that are not removed
Screening stool trial positive for enteric pathogens or Clostridium difficile toxin. History of ongoing, chronic or recurrent infectious disease
Positive HIV, Hepatitis B Virus (HBV),Hepatitis C Virus (HCV)
Severe infection, chronic infection, history of recurrent infections, active infection including TB
Malignancies or history of malignancies
History of congestive heart failure (NYHA: Grade III and IV), demyelinating disease, current signs or history of severe/ progressive/uncontrolled renal, hepatic, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease, or systemic lupus erythematosus (SLE)
History of transplanted organ, lymphoproliferative disease, any known malignancy
Previous allergy immunotherapy for anaphylaxis, hypersensitivity to ustekinumab or to any excipients, or metronidazole or ciprofloxacin
Previous use of a biologic agent targeting Interleukin 12 (IL12) and/or Interleukin 23 (IL 23), including but not limited to ustekinumab
Oral corticosteroids at a dose > 40 mg prednisone or its equivalent per day at inclusion (oral steroids should be at stable dose at least 7 days before inclusion)
Any current or previous use of the following within 8 weeks before the first trial agent injection : cyclosporine, tacrolimus, anti-TNF biologic agents or other agents intended to suppress or eliminate Tumor Necrosing Factor (TNF), and other biologics, including anti-integrin antibodies (approved or investigational), Janus Kinase (JAK) inhibitors (approved or investigational), or any current or previous use of an investigational agent
Non-autologous stem cell therapy or biologic agents that deplete B or T cells <12 months prior to baseline
Current or recent (less than 4 weeks) vaccination with attenuated live vaccines
Patients using a prohibited medication
Patients participating in another trial or being in a follow-up period for another trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note